-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $760

Benzinga·11/03/2026 19:21:07
Listen to the news
Citigroup analyst Eric Joseph maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $725 to $760.